Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2

TEL AVIV, Israel, May 9, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investors' awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure ...